GLMD:NASDAQGalmed Pharmaceuticals Ltd. Analysis

Galmed Pharmaceuticals (GLMD) is trading at $0.60, well below its 20‑day SMA (0.63) and far under the 200‑day SMA (0.90), with a neutral RSI (48.5) and a bearish MACD signal, indicating short‑term momentum weakness. Volatility is extreme, as shown by a 30‑day price swing of over 150% and a beta of roughly 2.3, while the stock’s market cap sits at just $4 M, making liquidity a concern.
Despite the technical headwinds, the company announced a breakthrough brain‑penetrating formulation of Aramchol and a pharmacokinetic study that boosted bioavailability by ~500%, providing a potent near‑term catalyst. The valuation appears **deeply discounted**, with a price‑to‑book of 0.25 and a negative PE, while the balance sheet holds $18 M in cash and no debt, giving the firm runway to advance its pipeline.